Eluvia™ Drug-eluting Vascular Stent System Demonstrates 12-month Primary Patency Of 96.1 Percent - Boston Scientific
Sep 28, 2015. MAJESTIC Trial Data Support Strong Safety Profile with Low Target Lesion Revascularization Rate. New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular Stent System reflect a primary patency rate1 of more than 96 percent. These results represent the highest 12-month primary patency reported for an interventional treatment of femoropopliteal artery lesions among comparable trials. The Eluvia Stent System is an advanced treatment option for patients with narrowing or blockages in the superficial femoral artery (SFA) or proximal popliteal artery (PPA), a result of peripheral artery disease (PAD).. Results from the MAJESTIC trial, which were presented at the Cardiovascular and Interventional Radiological Society ...http://www.bostonscientific.com/en-EU/news/newsroom-uk/peripheral-artery-disease/press-releases-2015/Eluvia-Drug-eluting-Vascular-Stent-System-Demonstrates-12-month-Primary-Patency-Of-96-1-Percent.html
Aortic distensibility and coronary artery bypass graft patency | Journal of Cardiothoracic Surgery | Full Text
Cho et al. showed that the patency rates were significantly higher in arterial grafts than in vein grafts at both one year and five years after CABG . Concordantly, in our study, the overall patency rate for LIMA was 85.4% and patency rate for saphenous grafts was 60% (total number of saphenous grafts was 91 and number of occluded saphenous grafts was 36). Goldman et al reported similar results. The 10-year patency in his study was 61% for SVGs and 85% for IMA grafts in a study by Goldman .. In our study in cases with and without saphenous graft obstruction; the mean number of years passed since bypass were 8.9 ± 5.6 and 7.8 ± 4.3; respectively, being significantly indifferent. Cases with patent and occluded LIMA had a mean number of years passed since ...https://cardiothoracicsurgery.biomedcentral.com/articles/10.1186/1749-8090-4-14
Radial Artery Versus Saphenous Vein Patency Randomized Trial | Circulation
In this single-center randomized study of aortocoronary bypass grafts to a single coronary territory, the angiographic patency of radial artery grafts at 5 years was significantly superior to that of saphenous vein grafts. This is the first trial to report the systematic repeat angiographic study of radial artery grafts at 5 years in a randomized trial. The radial artery grafts were significantly superior to the saphenous vein grafts in terms of both absolute patency and perfect patency. This study demonstrates the relatively frequent (23%) occurrence of occlusive disease in the body of patent vein grafts at 5 years. This was absent in the radial artery grafts. However, a number of the latter (n=5) were prone to suboptimal anastomoses. These stenoses were not severe and did ...http://circ.ahajournals.org/content/117/22/2859
Newsroom - MIROMATRIX MEDICAL Inc
Miromatrix will present its latest transplantable liver milestone at The Liver Meeting® hosted by the American Association for the Study of Liver Diseases (AASLD) on October 20-24 in Washington, D.C. Building on the company's successful liver re-endothelialization efforts, Miromatrix has advanced its ability to demonstrate functional liver vasculature by maintaining long-term vascular patency of its engineered liver grafts in a porcine model. A poster describing these advancements entitled "Towards Long-Term Vascular Patency of Tissue Engineered Liver Grafts: a Large Animal Study" will be presented at the conference on October 20th (Poster #712). Twenty-seven porcine liver grafts were seeded with endothelial cells cultured in bioreactors, 20 of which were evaluated in vitro to determine important factors that predict in vivo ...http://www.miromatrix.com/newsroom
Cardiac CAtheterization for Bypass Graft Patency Rate Optimization: the CABG-PRO Randomized-controlled Pilot Study - Full Text...
Aortocoronary bypass graft failure is common and is associated with high morbidity and mortality. Failure of saphenous vein grafts is more common than failure of internal mammary artery grafts. Whether early graft angiography can reduce bypass graft failure remains unknown. The Cardiac CAtheterization for Bypass Graft Patency Rate Optimization (CABG-PRO) randomized-controlled pilot study is a phase III, double-blind, randomized-controlled pilot trial that will randomize 170 patients undergoing coronary artery bypass graft surgery to early (before dismissal) graft angiography vs. no early graft angiography. Coronary angiography will be performed at 12 months, to determine whether compared to no early graft angiography, early graft angiography will result in:. ...https://clinicaltrials.gov/ct2/show/NCT01063491?term=Coronary+Angiography&recr=Open&fund=01&rank=2
Cardiac CAtheterization for Bypass Graft Patency Rate Optimization: the CABG-PRO Randomized-controlled Pilot Study - Full Text...
Aortocoronary bypass graft failure is common and is associated with high morbidity and mortality. Failure of saphenous vein grafts is more common than failure of internal mammary artery grafts. Whether early graft angiography can reduce bypass graft failure remains unknown. The Cardiac CAtheterization for Bypass Graft Patency Rate Optimization (CABG-PRO) randomized-controlled pilot study is a phase III, double-blind, randomized-controlled pilot trial that will randomize 170 patients undergoing coronary artery bypass graft surgery to early (before dismissal) graft angiography vs. no early graft angiography. Coronary angiography will be performed at 12 months, to determine whether compared to no early graft angiography, early graft angiography will result in:. ...https://clinicaltrials.gov/ct2/show/NCT01063491?term=coronary+artery+bypass+grafting+OR+coronary+bypass+surgery&recr=Open&fund=01&rank=1
Long-Term Patency Rate of Right Internal Thoracic Artery Bypass Via the Transverse Sinus | Circulation
Reduction in late cardiac events and improved long-term survivals compared with patients revascularized with the saphenous vein have been documented in patients receiving a LITA-to-LAD graft, with long-term (10-year) patency rates of LITA anastomosed to LAD reported to be ≈90%.1 2 3 4 5 6 7 8 9 10 With expectations of improving long-term survival, the use of bilateral ITA as a free graft, a Y graft, or an in situ graft has been advocated by some,14 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 but optimal use of the RITA is not established yet.. We have used the in situ RITA graft via the transverse sinus for revascularization of the circumflex and diagonal arteries with encouraging excellent angiographic early results, similar to those reported by Puig et al11 in 1984 and Buche et al12 in 1995. The ...http://circ.ahajournals.org/content/98/19/2043
Does patency after a vein collar and PTFE-bypass depend on sex and age? Re-analysis of a randomised trial
Aim. Randomized studies evaluating the effect of a vein collar at the distal anastomosis of PTFE-grafts show conflicting results. The study of the Joint Vascular Research Group (JVRG) of UK found improved primary patency while the Scandinavian Miller Collar Study (SCAMICOS) found neither any effect on patency nor on limb salvage after bypass to below-knee arteries. However, the Scandinavian patients were a decade older and predominately female compared to the British patients. Can this explain the conflicting result? less thanbrgreater than less thanbrgreater thanMethods: Primary patency with respect to sex, age and the use of vein collar were re-analysed in 345 patients from SCAMICOS with Kaplan-Meier life-table technique, log-rank test and Cox proportional hazards regression to evaluate any interaction between sex or age ...http://liu.diva-portal.org/smash/record.jsf?pid=diva2:538243
GORE VIABAHN® Versus Plain Old Balloon Angioplasty (POBA) for Superficial Femoral Artery (SFA) In-Stent Restenosis - Full Text...
This is a prospective, randomized, multi-center study recruiting patients with an in-stent restenosis in the superficial femoral artery. The safety and efficacity of the Viabahn endoprosthesis (W.L. Gore & Associates), a heparin-bonded endoprosthesis, is compared with plain old balloon angioplasty (POBA). In 4 Belgian and 2 German centers a total of 80 Patients will be recruited. Primary endpoint is primary patency at 12 months, defined as no evidence of restenosis or occlusion within the originally treated lesion based on color-flow duplex ultrasound (CFDU) measuring a peak systolic velocity ratio ≤2.5, and without target lesion revascularization (TLR) within 12 months.. In comparison to POBA, it is expected that the use of the Viabahn endoprosthesis (W.L. Gore & Associates) will result in greater 12 month primary patency of treated superficial femoral ...https://clinicaltrials.gov/ct2/show/NCT01108861
Influence of External Stent Size on Early Medial and Neointimal Thickening in a Pig Model of Saphenous Vein Bypass Grafting |...
Autologous saphenous vein continues to be one of the most widely used conduits for myocardial revascularization7 despite its disappointing long-term patency rate, with ≤50% of vein grafts occluded by 10 years after surgery.8 9 Late occlusion appears to result from both medial and neointimal thickening, caused by migration and proliferation of smooth muscle cells, and the late appearance of mature lipid-laden atherosclerotic plaques. These changes can compromise flow directly or promote thrombotic occlusion.1 10 Neither antiplatelet therapy nor avoidance of surgical preparative injury has been shown conclusively to eliminate medial and neointimal thickening in either experimental models or human vein grafts.1 2 8 Vessel wall thickening may be regarded as an intrinsic adaptation of the vein to arterial pressure,1 10 and grafting per se was recently shown to stimulate the production of ...http://circ.ahajournals.org/content/94/7/1741
Angiographic Predictors of 6-Month Patency of Bypass Grafts Implanted to the Right Coronary Artery | JACC: Journal of the...
This study shows that in patients randomly treated with either an RGEA or an SVG for a stenosis of the RCA, the proportion of grafts found occluded on systematic 6-month angiographic control is low and independent of the type of graft conduit; however, the flow pattern is significantly more affected by the angiographic characteristics of the grafted RCA for RGEA than for SVG. Consequently, most SVG but only a minority of RGEA remained functional when the MLD of the RCA was larger than a threshold value close to 1.0 mm.. Previous angiographic follow-up studies of RGEA have suggested that the graft patency might be affected by the stenosis of the recipient RCA, most likely as a result of competitive flow (3,15,16). The evaluation of stenosis severity was based on visual interpretation of post-operative coronary angiogram at the time of angiographic follow-up. In the present study, the evaluation of RCA ...http://www.onlinejacc.org/content/51/2/120
"Patency and Complication Rates of the Arteriovenous Fistula: A Systema" by Ahmed A. Al-Jaishi
Advantages of fistulas, which include long patency and low complication rates, were ascertained over two decades ago and may not apply to the contemporary dialysis population. We conducted a systematic review to summarize the patency and complication rates of fistulas from literature published after 1999. We screened 7,008 citations and 62 articles met our criteria. The risk of primary failure was 27% (95% confidence interval (CI): 23-32%). When primary failures were included, the primary and secondary patency rates were 59% (CI 53-64%) and 66% (CI 58-74%) at one year, respectively. The median rates of infection, ischemic steal syndrome, and thrombosis were 0.11 (range 0.01-1.0), 0.05 (range 0.0-0.1), and 0.27 (range 0.04-0.68) events per 1000 patient-days. When considering the fistula as the preferred option, the initial high risk of ...http://ir.lib.uwo.ca/etd/1431/
Endovascular Today - Interim BIOFLEX PEACE Data Presented for Biotronik's Pulsar-18 Stent in SFA Treatment
November 23, 2016-Biotronik announced that interim data from the BIOFLEX PEACE all-comers trial, which confirm the efficacy of the company's Pulsar-18 bare-metal, self-expanding stent (BMS SE) in the treatment of superficial femoral artery (SFA) disease, were presented at the 43rd annual VEITHsymposium, which was held November 15-19, 2016, in New York, New York. Jos C. van den Berg, MD, from Ospedale Regionale di Lugano, Switzerland, presented the results for Pulsar-18 during the symposium's main program on behalf of the trial's lead investigator, Michael Lichtenberg, MD, of the Vascular Center, Arnsberg, Germany.. BIOFLEX PEACE is a prospective, multicenter registry examining 151 patients in an all-comers enrollment. The study's primary endpoint is primary patency at 12 months.. According to the company, the available 12-month interim results demonstrate that the Pulsar-18 BMS SE is an effective treatment ...http://evtoday.com/2016/11/23/interim-bioflex-peace-data-presented-for-biotroniks-pulsar-18-stent-in-sfa-treatment?center=24
Enhancing Vein Graft Patency By Preserving Endothelial Function - Igor Voskresensky
Over a million coronary bypass procedures using human saphenous vein (HSV) are performed yearly worldwide. Nearly half of these grafts fail over a period of 12...http://grantome.com/grant/NIH/F32-HL110588-02
Parent vessel patency and incidence of different flow p | Open-i
Parent vessel patency and incidence of different flow patterns over the course of two weeks after mini port implantation in mice.https://openi.nlm.nih.gov/detailedresult.php?img=PMC4476576_pone.0130661.g005&req=4
Belgian Prospective Multicentre Registry to Evaluate Safety and Performance of the Optimed Stent in the Superficial Femoral...
Primary patency rate at 12 and 24 months as determined by Duplex ultrasound, defined as ,50% diameter restenosis(systolic velocity ratio no greater than 2.4) at the level of the treated lesion, without occurrence of target lesion revasularization between the index-procedure and the 12 and 24 months follow-up ...https://clinicaltrials.gov/ct2/show/NCT01499342
HEPARIN SODIUM 100 I.U./ML FLUSHING SOLUTION FOR MAINTENANCE OF PATENCY OF INTRAVENOUS DEVICES. | Drugs.com
Patient information for HEPARIN SODIUM 100 I.U./ML FLUSHING SOLUTION FOR MAINTENANCE OF PATENCY OF INTRAVENOUS DEVICES. Including dosage instructions and possible side effects.https://www.drugs.com/uk/heparin-sodium-100-i-u-ml-flushing-solution-for-maintenance-of-patency-of-intravenous-devices-leaflet.html
patency | patência
(KudoZ) English to Portuguese translation of patency: patência [Medical (general) (Medical) - Additional field(s): Medical: Instruments].https://www.proz.com/kudoz/english_to_portuguese/medical_general/2952085-patency.html
Patent US20060225747 - Vessel grafting method - Google Patents
Minimally invasive techniques utilized in bypass grafting are disclosed. For instance, a method of implanting and end portion of a graft in the body of a patient during a bypass grafting procedure includes the steps of (i) advancing a medical instrument within a circulatory system of said body, (ii) guiding a distal end of said medical instrument out of said circulatory system through an opening defined in said circulatory system after said medical instrument advancing step, (iii) advancing said end portion of said graft within said medical instrument after said guiding step, and (iv) securing said end portion of said graft to a blood to vessel of said circulatory system after said end portion advancing step.http://www.google.com.au/patents/US20060225747
US Patent # 5,749,375. Method for implanting an end portion of a graft within the body of a patient during a bypass...
A method for implanting an end portion of a graft within the body of a patient during a bypass grafting procedure includes the steps of (1) making an arteriotomy in a sidewall of a blood vessel at a fhttp://patents.com/us-5749375.html
A Stanford neuroscientist is presenting evidence of how chronic stress physically damages a region of the brain that processes learning and memory.http://www.wilx.com/home/headlines/276076.html?site=mobile
TCT: Stent for Claudication Shows Efficacy and Durability | Medpage Today
WASHINGTON -- Claudication patients given an investigational self-expanding stent were significantly more likely to maintain vessel patency at 12 months than those treated with percutaneous transluminhttps://www.medpagetoday.com/meetingcoverage/tct/7097
Home | Artegraft
Artegraft has been in continuous clinical use since 1970. The first vascular graft approved by the FDA, it has clinically proven higher primary and assisted patency rates over ePTFE grafts.http://artegraft.com/Home
Exteriorization utilizing PinPort
Envigo has developed an effective method for anchoring the PinPort and has achieved impressive patency information for catheterized animals using the PinPort exteriorization method.http://www.envigo.com/products-services/research-models-services/services/surgical-services/north-america-surgical-services/rat-catheterizations-options/exteriorization-utilizing-pinport.aspx
Lithium polymer battery - Wikipedia
Cells with solid polymer electrolytes have not reached full commercialization and are still a topic of research. Prototype cells of this type could be considered to be between a traditional lithium-ion battery (with liquid electrolyte) and a completely plastic, solid-state lithium-ion battery.. The simplest approach is to use a polymer matrix, such as polyvinylidene fluoride (PVdF) or poly(acrylonitrile) (PAN), gelled with conventional salts and solvents, such as LiPF6 in EC/DMC/DEC.. Nishi mentions that Sony started research on lithium-ion cells with gelled polymer electrolytes (GPE) in 1988, before the commercialisation of the liquid-electrolyte lithium-ion cell in 1991. At that time polymer batteries were promising and it seemed polymer electrolytes would become indispensable. Eventually, this type of cell went into the market in 1998. However, Scrosati argues that, in the strictest sense, gelled membranes cannot be classified as "true" polymer electrolytes, ...https://en.wikipedia.org/wiki/Lithium_ion_polymer_battery